Clinical Trial Feasibility Intelligence

The Zonra model
identifies where
enrollment fails
before it does.

Zonra applies a proprietary feasibility framework to rare and genetic disease programmes, giving sponsors the intelligence to act on site strategy, patient identification, and geographic scope before any spend is committed.

80%
Of trials fail to meet
enrollment timelines
up to $8M
Lost per day of
enrollment delay
55%
Of trials terminated
due to poor enrollment
55% of trials are terminated due to poor enrollment •  Enrollment delays cost sponsors up to $8M per day •  Rare diseases in children: 72% are genetic in origin •  Gene therapy programmes in active development: 400+ globally •  Fewer than 20% of candidate sites qualify for gene therapy •  Africa: 17% of world population. 1.3% of global clinical trials •  55% of trials are terminated due to poor enrollment •  Enrollment delays cost sponsors up to $8M per day •  Rare diseases in children: 72% are genetic in origin •  Gene therapy programmes in active development: 400+ globally •  Fewer than 20% of candidate sites qualify for gene therapy •  Africa: 17% of world population. 1.3% of global clinical trials
The Zonra Framework

Four analytical layers.
One enrollment risk score.

Every programme runs through the same four-layer framework. The output is a scored risk profile with site-level recommendations, ready to act on.

Layer 01
Patient pool intelligence
Diagnosed and undiagnosed population estimates, genotype stratification, geographic clustering, and patient registry gap analysis. The model locates where patients are before site selection begins.
Layer 02
Site capability assessment
Gene therapy infrastructure readiness, long-term follow-up capacity, vector handling requirements, investigator experience scoring, and competing trial load. Sites are ranked globally.
Layer 03
Competitive landscape mapping
Active and planned trials competing for the same patient pool. Sponsor profiles, projected enrollment timelines, and patient access pressure modeled across each geography.
Layer 04
Enrollment Risk Index
A composite score synthesising all four layers, with site-level and region-level mitigation recommendations. A decision-ready intelligence document, not a research summary.
How It Works

Access the intelligence
before the clock starts.

01
Programme scoping
Disease area, development stage, geography, and known constraints. The framework is calibrated to your programme, not applied as a template.
02
Framework analysis
All four layers run across your programme, drawing on epidemiological registries, published literature, proprietary site data, and competitive intelligence sources.
03
Intelligence delivery
A structured intelligence document with your Enrollment Risk Index, a scored site list, and mitigation recommendations. Followed by a live readout with your team.
04
Timeline
Three to four weeks from scope call to delivery, within pre-IND and pre-CRO engagement windows.
Extended Capability

The Zonra model covers geographies that standard feasibility tools ignore.

Most feasibility databases are built on Western site networks. For sponsors whose programmes require diverse patient populations, or who are exploring sites beyond Europe and North America, the standard model has a structural gap.

Zonra's extended coverage includes Africa site and patient mapping — qualified investigator identification, site readiness assessment, and patient registry analysis across African geographies. Built on primary research, not inherited assumptions.

Discuss Extended Coverage →
400+
Gene therapy
programmes globally
55%
Of trials terminated
for poor enrollment
20%
Of sites qualify
for gene therapy
$8M
Lost per day of
enrollment delay
Interactive Tool

Try the Enrollment
Risk Index.

Enter your programme parameters and receive a scored enrollment risk assessment across all four Zonra framework layers in under 2 minutes. No login, no installation.

Disease area, geography, therapy modality, constraints
Composite Enrollment Risk Index score (0–100)
Layer-by-layer breakdown with risk flags
Africa Extended Module for African geographies
FDORA Diversity Action Plan identification
Open the Risk Index Tool →

Directional assessment only. A full Zonra engagement delivers complete intelligence in 3–4 weeks.

ZONRA · Enrollment Risk Intelligence Engine
LAYER 04 — ENROLLMENT RISK INDEX
93
HIGH RISK
0 — Lower100 — High Risk
Patient Pool
95
Site Capability
60
Competitive
35
Risk Index
63
◈
Africa Extended Module Engaged
Primary research · Nigeria & sub-Saharan Africa
Who Engages Zonra

Programmes where the cost
of uncertainty is highest.

01
Pre-Series B biotechs
Gene therapy and rare disease developers approaching pivotal studies. The Zonra model validates enrollment feasibility before the programme is locked in CRO contracts.
02
Academic spinouts
Rare disease programmes moving from academic discovery into clinical development. Zonra provides the enrollment evidence base that IND submissions require.
03
Sponsors navigating diversity requirements
Programmes required to demonstrate diverse patient enrollment under FDORA or similar mandates. Zonra identifies qualified sites and patient populations in underrepresented geographies.

Know before
you commit.

Tell us about your programme. Zonra will scope the right engagement for your disease area, geography, and development stage.

MARIAM@ZONRA.BIO → Connect on LinkedIn